广西医学
廣西醫學
엄서의학
GUANGXI MEDICAL JOURNAL
2013年
4期
399-401
,共3页
陈英%刘波%段小嬿%吴相慰%关浩增
陳英%劉波%段小嬿%吳相慰%關浩增
진영%류파%단소연%오상위%관호증
心肌梗死%普伐他汀%炎性因子
心肌梗死%普伐他汀%炎性因子
심기경사%보벌타정%염성인자
Myocardial infarction%Pravastatin%Inflammatory marker
目的观察短期大剂量普伐他汀对急性心肌梗死患者C反应蛋白(CRP)、CD40L的影响.方法将72例急性心肌梗死患者按随机数字表法分为A、B两组,每组36例,A组口服普伐他汀片40 mg/d,B组口服普伐他汀片20 mg/d,治疗前及治疗3 d 后分别测定CRP 和CD40L.结果两组患者血清 CRP 和CD40L在治疗后3 d均有明显下降(P<0.05),但以40 mg普伐他汀组更为明显(P<0.01).结论急性心肌梗死早期使用普伐他汀可抑制患者炎性反应,且大剂量效果更好.
目的觀察短期大劑量普伐他汀對急性心肌梗死患者C反應蛋白(CRP)、CD40L的影響.方法將72例急性心肌梗死患者按隨機數字錶法分為A、B兩組,每組36例,A組口服普伐他汀片40 mg/d,B組口服普伐他汀片20 mg/d,治療前及治療3 d 後分彆測定CRP 和CD40L.結果兩組患者血清 CRP 和CD40L在治療後3 d均有明顯下降(P<0.05),但以40 mg普伐他汀組更為明顯(P<0.01).結論急性心肌梗死早期使用普伐他汀可抑製患者炎性反應,且大劑量效果更好.
목적관찰단기대제량보벌타정대급성심기경사환자C반응단백(CRP)、CD40L적영향.방법장72례급성심기경사환자안수궤수자표법분위A、B량조,매조36례,A조구복보벌타정편40 mg/d,B조구복보벌타정편20 mg/d,치료전급치료3 d 후분별측정CRP 화CD40L.결과량조환자혈청 CRP 화CD40L재치료후3 d균유명현하강(P<0.05),단이40 mg보벌타정조경위명현(P<0.01).결론급성심기경사조기사용보벌타정가억제환자염성반응,차대제량효과경호.
@@@@Objective To observe the effect of short-term large dose of pravastatin on the change of C-reactive protein (CRP),CD40L in patients with acute myocardial infarction.Methods Seventy-two patients with acute myocardial infarction were divided into Group A and Group B according to the random number table:Group A(n=36) were administered orally pravastatin of 40 mg/d,and Group B(n=36) were administered orally pravastatin of 20 mg/d.The serum levels of CRP, CD40L were detected before treatment and 3 days after treatment,respectively.Results The serum levels of CRP,CD40L decreased significantly 3 days after treatment in both groups(P<0.05),which were superior in Group A(P<0.01). Conclusion The inflammatory reaction could be inhibited in acute myocardial infarction patients treated with pravastatin in the early stage,and the effect of large dose of pavastatin is better .